Oman vs Timor-Leste: HIV/AIDS deaths averted by antiretroviral therapy
Oman
107.42 deaths
in 2024
Timor-Leste
93.18 deaths
in 2024
Oman rank
124th
Timor-Leste rank
126th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Oman
- Timor-Leste
How they compare
Oman currently reports 107.42 deaths against 93.18 deaths in Timor-Leste, a difference of 14.24 deaths.
That makes Oman's figure about 1.2 times Timor-Leste's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Timor-Leste ahead.
Oman ranks 124th and Timor-Leste ranks 126th of 157 countries.
Oman has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Oman | Timor-Leste | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 32.99 deaths | 1.78 deaths | 31.2 deaths | Oman |
| 2010s | 53.22 deaths | 23.13 deaths | 30.1 deaths | Oman |
| 2020s | 86.92 deaths | 74.8 deaths | 12.12 deaths | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Oman or Timor-Leste?
- Oman, at 107.42 deaths against 93.18 deaths in Timor-Leste as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Oman and Timor-Leste?
- 14.24 deaths, with Oman ahead.
- How many years of comparable data are there for Oman and Timor-Leste?
- 35 years are reported by both, from 1990 to 2024.
- How do Oman and Timor-Leste rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Oman ranks 124th and Timor-Leste ranks 126th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.